Opendata, web and dolomites


Saving millions of lives by enabling an effective treatment for Heart Failure patients; V-LAP, a revolutionary, miniaturized implant and its dedicated wearable device.

Total Cost €


EC-Contrib. €






 V-LAP project word cloud

Explore the words cloud of the V-LAP project. It provides you a very rough idea of what is the project "V-LAP" about.

hospitalization    trough    data    prescription    swelling    implantable    day    disruptive    measured    synchronize    monitor    lv    patient    total    invasive    sudden    left    industrialization    hemodynamic    unable    code    ventricular    belt    adjust    hospital    flow    color    clinicians    minimally    decompensate    inductive    daily    12    vectorious    sent    worldwide    public    global    levels    leg    transition    65    device    threatening    healthcare    earliest    ac    diabetes    miniaturized    ing    invasively    powered    meet    ineffective    quality    chronic    clothes    body    covered    adhf    company    plan    symptoms    lap    excess    decreasing    28    life    events    glucose    hf    catheter    coupling    medications    30    weeks    patients    collected    efficacy    green    edema    detecting    98    least    filling    trials    back    min    pump    takes    free    mobile    aged    tiredness    clinical    indicator    dyspnea       fluids    heart    blood    promptly    worsening    procedure    external    patents    yellow    portfolio    battery    website    red    worn    expenditure    provider    people    nhs    outcome    completely    predict    organs    causes    mortality    acute    pressure   

Project "V-LAP" data sheet

The following table provides information about the project.


Organization address
postcode: n.a.
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-05-01   to  2017-09-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

Heart failure (HF) is a chronic condition affecting 1 in 5 people aged over 65 worldwide: heart is unable to pump enough blood flow to meet the body needs. The resulting excess of fluids in body and organs causes dyspnea, edema, leg swelling and tiredness, decreasing patients’ life quality. The sudden worsening of symptoms is called Acute Decompensate Heart Failure: a life-threatening condition with 30% mortality within 12 weeks. HF costs are high: 28 B€/year to EU NHS, 2% of total healthcare expenditure, the major part due to hospitalization. There is today a global call to increase awareness in HF, whose management is still highly ineffective. The transition from HF to the acute condition takes weeks but its earliest indicator, an increase in left ventricular filling pressure (LV), can only be measured invasively, in a hospital. Vectorious’ disruptive device is a miniaturized, battery-free, implantable hemodynamic monitor capable of detecting the rise in LV during patient’s daily life. The implantable, completely covered by Vectorious’ patents portfolio, is deployed trough a minimally invasive, catheter-based procedure. A belt-like external device is worn by the patient over the clothes 3 min/day: via inductive AC coupling, the implantable is powered so pressure data can be collected and sent back to the external unit which synchronize with the patient’s mobile device and with a dedicated website for the healthcare provider. A green/yellow/ red color code widely known among HF patients allows them to promptly adjust their medications, according with their clinicians’ prescription. V-LAP will be able to predict at least 98% ADHF events, HF management will become as simple as manage glucose levels in diabetes. During Phase 1 project the Company will assess scale-up industrialization plan, product development and clinical trials to be deployed in Europe to show the system efficacy on patient outcome and public healthcare costs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "V-LAP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "V-LAP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.1.;H2020-EU.2.3.1.)

Starcounter (2017)

In-Memory Computing and Artificial Intelligence Platform for Building Next Generation Enterprise Software

Read More  

oWBI (2018)

Osmotic Wearable Bolus Injector (oWBI) for viscous drug delivery

Read More  

scanvid (2017)

ScanVid - One-Click Integrated Access to Product-related Digital Content

Read More